Table 2.
Comparison of voriconazole and fluconazole prophylaxis in allogeneic HSCT and ASCT settings
| Variable | Antifungal prophylaxis | |||
|---|---|---|---|---|
| N | Voriconazole | Fluconazole | P | |
| IFI in Allogeneic HSCT | ||||
| +ve | 10 | 4 (40%) | 6 (60%) | 0.452 |
| −ve | 4 | 13 (54.2%) | 11 (45.8%) | |
| IFI in ASCT | ||||
| +ve | 10 | 4 (40%) | 6 (60%) | 0.457 |
| −ve | 26 | 14 (53.8%) | 12 (46.2%) | |
| Need for preemptive antifungal treatment in allogeneic HSCT | ||||
| +ve | 15 | 7 (46.7%) | 8 (53.3%) | 0.730 |
| −ve | 19 | 10 (52.6%) | 9 (47.4%) | |
| Need for preemptive antifungal treatment in ASCT | ||||
| +ve | 10 | 5 (50%) | 5 (50%) | 1.000 |
| −ve | 26 | 13 (50%) | 13 (50%) | |
| Replacement of antifungal agent by another one because of side effects in ASCT | ||||
| +ve | 4 | 1 (25%) | 3 (75%) | 0.289 |
| −ve | 32 | 17 (53.1%) | 15 (46.9%) | |
| IFI requiring late hospitalization in allogeneic HSCT | ||||
| +ve | 4 | 1 (25%) | 3 (75%) | 0.287 |
| −ve | 30 | 16 (53.3%) | 14 (46.7%) | |
| IFI requiring late hospitalization in ASCT | ||||
| +ve | 2 | 0 (0%) | 2 (100%) | 0.146 |
| −ve | 34 | 18 (52.9%) | 16 (47.1%) | |
| IRD in allogeneic HSCT | ||||
| +ve | 4 | 2 (50%) | 2 (50%) | 1.000 |
| −ve | 30 | 15 (50%) | 15 (50%) | |
| IRD in ASCT | ||||
| +ve | 2 | 0 (0%) | 2 (100%) | 0.146 |
| −ve | 34 | 18 (52.9%) | 16 (47.1%) | |
| Type of probable/proven IFI in allogeneic HSCT | ||||
| −ve | 27 | 15 (55.6%) | 12 (44.4%) | 0.282 |
| MM | 2 | 0 (0%) | 2 (100%) | |
| IA | 5 | 2 (40%) | 3 (60%) | |
| IC | 0 | 0 (0%) | 0 (0%) | |
| Type of probable/proven IFI in ASCT | ||||
| −ve | 30 | 15 (50%) | 15 (50%) | 1.000 |
| MM | 0 | 0 (0%) | 0 (0%) | |
| IA | 6 | 3 (50%) | 3 (50%) | |
| IC | 0 | 0 (0%) | 0 (0%) | |
| Sites of probable/proven IFI in allogeneic HSCT | ||||
| −ve | 27 | 15 (55.6%) | 12 (44.4%) | 0.282 |
| PNS | 2 | 0 (0%) | 2 (100%) | |
| Pulmonary | 5 | 2 (40%) | 3 (60%) | |
| Sites of probable/proven IFI in ASCT | ||||
| −ve | 30 | 15 (50%) | 15 (50%) | 1.000 |
| Pulmonary | 6 | 3 (50%) | 3 (50%) | |
| Mean duration of hospitalization in allogeneic HSCT ± SD, days (range) | 36.2 ± 16.5 (21–87) | 36.9 ± 19.8 (17–81) | 0.903 | |
| Mean duration of hospitalization in ASCT ± SD, days (range) | 27.3 ± 11.2 (16–53) | 31.3 ± 27.4 (12–109) | 0.570 | |
IFI invasive fungal infection, HSCT hematopoietic stem cell transplantation, ASCT autologous stem cell transplantation, IRD IFI-related death, MM mucormycosis, IA invasive aspergillosis, IC invasive candidiasis, PNS paranasal sinuses, SD standard deviation, N number